Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Barber Say syndrome (BSS) is a rare ectodermal dysplasia with neonatal onset characterized by congenital generalized hypertrichosis, atrophic skin, ectropion and microstomia.
Features include always present findings: Hypertrichosis, Bulbous nose, and Wide mouth; and very common findings: Ectropion. 47 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 3 | Dry skin, Redundant skin, Premature skin wrinkling |
TWIST2 function has not been fully characterized.
Barber-Say syndrome is associated with mutations in the TWIST2 gene on chromosome 2.
Genetic testing for TWIST2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Barber-Say syndrome has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 1 very common feature, 9 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Barber-Say syndrome.
32 publications have been identified in PubMed for Barber-Say syndrome. Research spans Case Report / Case Series (75%), Review / Meta-Analysis (9%), and Clinical Trial Publication (6%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 24 | 75% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 1:00 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Barber-Say syndrome
3 |
Hypoplasia of the maxilla, High palate, Mandibular prognathia |
Brain and nerves | 2 | Intellectual disability, Delayed speech and language development |
Arms and legs | 2 | Prominent digit pad, Clinodactyly of the 5th finger |
Ears | 1 | Hearing loss (hearing impairment) |
Muscles | 1 | Dermal atrophy |
3 |
9% |
Clinical study results | 2 | 6% |
Other research | 1 | 3% |
Testing and diagnosis research | 1 | 3% |
Laboratory research | 1 | 3% |
Neumann A (2026). [PMID: 41812671](https://pubmed.ncbi.nlm.nih.gov/41812671/). *Rofo*. [Diagnostic / Biomarker]
Demetriades AK (2026). [PMID: 42174133](https://pubmed.ncbi.nlm.nih.gov/42174133/). *Spinal Cord*. [Review / Meta-Analysis]
Temel M (2026). [PMID: 41770212](https://pubmed.ncbi.nlm.nih.gov/41770212/). *J Spinal Cord Med*. [Case Report / Case Series]
Li W (2026). [PMID: 41992358](https://pubmed.ncbi.nlm.nih.gov/41992358/). *J Med Case Rep*. [Case Report / Case Series]
Lee YJ (2026). [PMID: 42155976](https://pubmed.ncbi.nlm.nih.gov/42155976/). *Am J Phys Med Rehabil*. [Clinical Trial Publication]
Blackbourn LW (2026). [PMID: 41728463](https://pubmed.ncbi.nlm.nih.gov/41728463/). *Cureus*. [Case Report / Case Series]
Elmuradova U (2026). [PMID: 41716878](https://pubmed.ncbi.nlm.nih.gov/41716878/). *Brain Spine*. [Case Report / Case Series]
Onishi E (2025). [PMID: 40296979](https://pubmed.ncbi.nlm.nih.gov/40296979/). *Cureus*. [Case Report / Case Series]
Wackerly R (2025). [PMID: 41409851](https://pubmed.ncbi.nlm.nih.gov/41409851/). *Surg Neurol Int*. [Case Report / Case Series]
Guo G (2025). [PMID: 41394164](https://pubmed.ncbi.nlm.nih.gov/41394164/). *Front Surg*. [Case Report / Case Series]
AI-curated news mentioning Barber-Say syndrome
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.